Literature DB >> 8699071

Mucosal antibodies to human cytomegalovirus glycoprotein B occur following both natural infection and immunization with human cytomegalovirus vaccines.

J B Wang1, S P Adler, S Hempfling, R L Burke, A M Duliège, S E Starr, S A Plotkin.   

Abstract

Because antibodies against human cytomegalovirus (HCMV) glycoprotein B (gB) neutralize, levels of IgG, secretory IgA (sIgA), and mucosal IgA1 antibodies to HCMV were measured in saliva and nasal washes. Ten seronegative adults lacked these antibodies, but of 10 naturally seropositive adults, 10 had IgG to gB, 5 had sIgA, and 0 had mucosal IgA. Among 12 recipients of a live HCMV vaccine, 8 had IgG to gB, 4 had sIgA, and 2 had mucosal IgA in samples collected 10-20 months after immunization; of 10 recipients of a gB vaccine, 8 had IgG to gB, 7 had sIgA, and 7 had mucosal IgA in samples collected just before or 1 month after a booster. IgG to gB and neutralizing titers in serum correlated with IgG to gB in mucosal samples. IgG to gB was in the saliva of 25 of 26 subjects with serum neutralizing titers > 1:64. Serum neutralizing titers > 1:64, whether induced by vaccine or wild type virus, are associated with mucosal IgG to HCMV.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8699071     DOI: 10.1093/infdis/174.2.387

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  20 in total

1.  Intrahost Dynamics of Human Cytomegalovirus Variants Acquired by Seronegative Glycoprotein B Vaccinees.

Authors:  Ravit Arav-Boger; Sallie R Permar; Cody S Nelson; Diana Vera Cruz; Melody Su; Guanhua Xie; Nathan Vandergrift; Robert F Pass; Michael Forman; Marie Diener-West; Katia Koelle
Journal:  J Virol       Date:  2019-02-19       Impact factor: 5.103

2.  Neutralizing activity of saliva against cytomegalovirus.

Authors:  Frances M Saccoccio; Mary K Gallagher; Stuart P Adler; Michael A McVoy
Journal:  Clin Vaccine Immunol       Date:  2011-07-27

3.  Immune Correlates of Protection Against Human Cytomegalovirus Acquisition, Replication, and Disease.

Authors:  Cody S Nelson; Ilona Baraniak; Daniele Lilleri; Matthew B Reeves; Paul D Griffiths; Sallie R Permar
Journal:  J Infect Dis       Date:  2020-03-05       Impact factor: 5.226

Review 4.  Prospects of a vaccine for the prevention of congenital cytomegalovirus disease.

Authors:  Bodo Plachter
Journal:  Med Microbiol Immunol       Date:  2016-08-12       Impact factor: 3.402

5.  Salivary antibodies to cytomegalovirus (CMV) glycoprotein B accurately predict CMV infections among preschool children.

Authors:  J B Wang; S P Adler
Journal:  J Clin Microbiol       Date:  1996-10       Impact factor: 5.948

6.  Stanley Plotkin: the bright spark of cytomegalovirus vaccines.

Authors:  Edward S Mocarski
Journal:  Med Microbiol Immunol       Date:  2015-03-20       Impact factor: 3.402

7.  A Phase 1 Study of 4 Live, Recombinant Human Cytomegalovirus Towne/Toledo Chimera Vaccines in Cytomegalovirus-Seronegative Men.

Authors:  Stuart P Adler; Anne-Marie Manganello; Ronzo Lee; Michael A McVoy; Daniel E Nixon; Stanley Plotkin; Edward Mocarski; Josephine H Cox; Patricia E Fast; Pavlo A Nesterenko; Susan E Murray; Ann B Hill; George Kemble
Journal:  J Infect Dis       Date:  2016-08-11       Impact factor: 5.226

Review 8.  Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant.

Authors:  Robert F Pass
Journal:  J Clin Virol       Date:  2009-07-31       Impact factor: 3.168

9.  The frequency of pregnancy and exposure to cytomegalovirus infections among women with a young child in day care.

Authors:  Beth C Marshall; Stuart P Adler
Journal:  Am J Obstet Gynecol       Date:  2008-10-09       Impact factor: 8.661

Review 10.  Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant.

Authors:  Maria Grazia Revello; Giuseppe Gerna
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.